FDA U.S. FOOD & DRUG

OFFICE OF REGULATORY AFFAIRS

FDA INSPECTIONS SUMMIT

15TH Annual

November 17, 2020



ELIZABETH MILLER, PHARM.D.

FD/

Assistant Commissioner for Medical Products and Tobacco Operations Regulatory Affairs

Keynote Address



ORA'S ROLE AND FUNCTIONS


ORA Maximizes Compliance of FDA Regulated Products and Minimizes Risks Associated with Those Products



INSPECTIONS: ORA'S GLOBAL REACH

ORA's Global Inspections:

United States	Conch Republic	Japan.	Separat
Albania	Denmark	Jedan.	Sirvakia
Argentina	Dominican Republic their	Kores the Resuble of	Sloversia
Arminia	Ecuator .	Latvia	South Alvica
Australia	Externa	Litteatia	Spann -
Austria	Yante Mands	Macerbonia	Suriname
Reformation	Fil	Malaysia	Sweden
fistants.	Finland	Malta	Switzerland
Belatus.	Fance	Narshall talands	Taluan
Belgium	Georgia	Mauritius.	Thalaret
Bellev	Germany	Mexico	Tience
Bentin	Guru	Maldona	Trinidad & Tulbage
Bullvia	Greenie	Manager	Turkey
Bunnia Hercogovina	Grenada	Netherland:	Likesine:
fruit	Gusternale	New Zealand	United Anali Environme
Rulparta	Guana	Morria	United Kingdom
Burna Myanmari	Hondurat	Norway	Uruguay
Carrinofia	Hong Kong SAR	Parama	Vietnaro
Canada	Hungary	Para	Western Sampa
Cape Vietly	Rolland.	Philippines	
Chie	india	Poland	É.
China	Indonesia	Portugal	Countries Where
Coloribia	inland	Remania	ORA Canducts
Costa Rica	Interio	Rents	Inspections.
Crualia	Taly .	Senegal	
Cigna	Jamaira -	Serbas	
e juji sas	10100	10000	








UPDATES

- New ORA Leadership
 - Associate Commissioner for Regulatory Affairs
 - Deputy Associate Commissioner for Regulatory Affairs
 - Assistant Commissioner for Medical Products and Tobacco Operations





FDA



FDA ACTIVITIES DURING COVID-19 AS RELATED TO MEDICAL PRODUCTS

- March 10 and 18 announcements to postpone foreign and domestic inspections
- Continued mission critical inspections on a case-by-case basis
 - Potentially serious public health hazard
 - Essential product shortage
 - Pre-approval inspection needed for novel or pandemic-related product or treatment
- Using statutory authorities to collect records in lieu of inspections and other tools



COVID-19 ADVISORY RATING SYSTEM

- Created to determine when and where it is safest to conduct domestic inspections
- Uses real-time data to assess the number of COVID-19 cases in a local area
- · Helps to protect our staff and the employees of the facilities we regulate

FDA ACTIVITIES DURING COVID-19 AS RELATED TO MEDICAL PRODUCTS

- Office of Medical Products and Tobacco Operations (OMPTO)
 - Conducted mission critical, onsite drug & BIMO inspections
 - Section 704(a)(4) of the Federal, Food, Drug, and Cosmetic Act. This provision, in place since Food and Drug Administration Safety and Innovation Act (FDASIA 2012) allows for records request in advance or in lieu of an inspection
 - Section 706, Records for inspection section request includes description of information requested, reasonable timeframe, within reasonable limits, reasonable manner.

RECORDS REQUEST


- Section 704(a)4 of the Federal Food and Drug Cosmetic Act
- Mutual Recognition Agreement
- Both approaches help inform decisions related to drug approvals and shortages



FDA

OPERATION QUACK HACK

- Leverages agency expertise and analytics to protect consumers from fraudulent products
- Online marketplaces have removed more than 500 products at FDA's request
- Information on reporting fraud or violations is found on <u>https://www.fda.gov/safety/report-</u> problem-fda/reporting-unlawful-salesmedical-products-internet







PRIORITIZED DOMESTIC INSPECTIONS

- Pre-announced
- Ensure safety of employees
- Personal protective equipment



EXPLORING REMOTE REGULATORY ASSESSMENTS

- Voluntary mechanism to help make important regulatory decisions
- Involves a remote view of records that a firm is required to maintain for the FDA's review



MEDICAL PRODUCT PROGRAM UPDATES

- Biologics
 - Workshop for the Reproductive Tissue
 - On-site investigations intended to support COVID-19 countermeasures

FDA

MEDICAL PRODUCT PROGRAM UPDATES

- Medical Devices
 - Remote QSIT assessments
 - Anticipating 2021 FDA publishing Proposed Rule for transition of quality system regulation to ISO 13485:2016

MEDICAL PRODUCT PROGRAM UPDATES

- Pharma Program
 - Center of Excellence for Outsourcing Compounding virtual conference
 - Expanding MRA
 - Mission Critical Assignments (inspections & sample collections)



OPTIMIZING OUR INSPECTION PROCESS

- COVID-19 highlighted interconnected global manufacturing and supply system
- Opportunities to optimize inspectional work through process improvements and increased collaboration with stakeholders
- Interim report available at the end of 2020 and a final report in summer of 2021





ONGOING ACTIVITIES

- Hand Sanitizers
- Collaboration on APIs & Sterile Finished Dosage
- Compliance



GOING FORWARD

- Current challenges present opportunities to reassess how we work
- ORA will continue to work to enhance our response
- Continued collaboration with other regulators
- PICS & Inspection Reliance





